作者: Mellar P. Davis , Geoffrey Mitchell
DOI: 10.1097/SPC.0B013E32835931DB
关键词:
摘要: Purpose of review Changes in drug trial designs oncology, which involve targeted therapies and well genotyped cancers have important implications to the present used for analgesic development. Recent findings Pain phenotypes influence responses. Analgesics can now be pain phenotypes. IMMPACT strategies should modified using pharmacokinetic- pharmacodynamics phase II-III commonly oncology. Summary Modifying will facilitate development analgesics improve 'signal-to-noise' ratio over strategies, are largely based on severity changes intensity time.